The U.S. Food and Drug Administration on Friday allowed the use of GlaxoSmithKline’s (GSK.L) Boostrix vaccine during the third trimester of pregnancy to prevent whooping cough in infants younger than two months of age.

“When the Boostrix vaccine is given during pregnancy, it boosts antibodies in the mother, which are transferred to the developing baby,” the agency said.

While FDA’s approval of Boostrix has always included its use during pregnancy to protect the vaccinated individual, the latest decision expands its use to help prevent pertussis, commonly known as whooping cough, in infants younger than two months.